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Abstract

Results

In order to better understand the development of hereditary leiomyomatosis
associated renal cell carcinoma (HLRCC), a patient derived xenograft (PDX) animal
model was generated and characterized in our lab from a 24-year-old patient's
resected HLRCC tumor. In addition to the animal model, we are also retrospectively
determining the number of type 2 papillary RCC patients at MD Anderson that had
reduced fumarate hydratase (FH) expression.

HLRCC PDX and normal kidney tissue have varying levels of HIF and GLS expression.
We carried out gel electrophoresis and Western Blot analysis to measure the
expression of lysates from 3 unique tumors from our HLRCC PDX model as well as
lysates of normal human kidney tissue. This analysis revealed the HLRCC PDX
model had higher expression of HIF1α and HIF2α (Figure 3a, 3b). HLRCC PDX
model also displayed higher expression of GLS1 but had similar GLS2 expression
levels when compared to normal human kidney tissue. FH displayed lower levels of
expression in the HLRCC PDX model when compared to the normal human kidney
tissue. (Figure 3c). Expression of B-actin and Histone H-3 (Figure 3a, 3b), loading
controls, remained constant for HLRCC PDX and normal human kidney tissue.

Background

Hereditary Leiomyomatosis

STR Fingerprinting of HLRCC PDX tissue and HLRCC patient tissue reveal genetic
similarity.
To further confirm the genetic similarity of the HLRCC PDX model and the
HLRCC patient tissue, short tandem repeat (STR) analysis was utilized to
compare alleles at different loci between the two samples. Tandem repeats
confirmed that HLRCC PDX tissue was genetically similar to the original
HLRCC patient tissue (Table 1).

Table 1. STR Fingerprinting of HLRCC PDX tissue and HLRCC patient tissue.

• Autosomal dominant
• Characterized by multiple cutaneous leiomyomas, early onset uterine leiomyomas,
and type 2 papillary RCC
• Mutations in FH, an essential enzyme in the citric acid cycle
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Figure 1. Clinical Manifestation of HLRCC. (a) Cutaneous leiomyomas resulting
from HLRCC. (b, c) CT imaging of type 2 papillary RCC.
Fumarate hydratase (FH) mutation
• Mutations in FH increase patient risk for the development of type 2 papillary renal
cell carcinoma (RCC), a rare and aggressive type of renal cancer
• Results in a decrease in FH expression and a buildup of fumarate --> leads to the
stabilization of hypoxia inducible factor (HIF)
• FH-deficient RCC --> increased glutamine-dependent carboxylation for energy
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Figure 3. Final Western Blots of lysates from 3 unique HLRCC PDX tumors
and lysates from normal human kidney tissue. (a) HLRCC PDX tissue displayed
increased expression of HIF2α and GLS1. (b) HLRCC PDX tissue displayed
increased expression of HIF1α. (c) FH had lower expression in HLRCC PDX
tissue.

Methods
HLRCC PDX Animal Model
• Implanted HLRCC resected tumor tissue from a 24-year-old woman into NOD scid
gamma (NSG) mice subcutaneously
• Tumors harvested when they reached ≈ 1500 mm3 and resected tumor tissue was
passaged into another set of NSG mice
• At the conclusion of the 3rd passage, tumor tissue from PDX model was subjected
to a series of analytical studies

Histology of HLRCC PDX tissue and HLRCC patient tissue reveal
morphological similarity.
We next sought to determine the histological and genetic similarity between
HLRCC PDX tissue and the original HLRCC patient tissue. Analysis of tissue
histology revealed that HLRCC PDX tissue and HLRCC patient tissue are
morphologically similar per MD Anderson pathologist, Dr. Rao.
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Conclusions
1) HLRCC PDX animal model displayed
• Increased expression of HIF1α and HIF2α
• Increased expression of GLS1
• Decreased expression of FH compared to normal human kidney
tissue
2) We generated an HLRCC PDX animal model that was morphologically and
genetically similar to the original HLRCC patient tissue
Our findings illustrate 1) FH-deficient HLRCC leads to an increase in HIF1α and
HIF2α. This increase results in increased expression of GLS1. 2) FH-deficient
HLRCC's reliance on glutamine-dependent carboxylation in place of oxidative
phosphorylation also leads to an increase GLS1.

Discussion

HLRCC
Resected
Tumor Tissue
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We hypothesize that HLRCC is glutamine addicted and requires glutamine
for sufficient metabolism. We also hypothesize that the accumulation of
fumarate due to FH-deficient HLRCC will lead to the activation of specific proteins
associated with oncogenesis. These proteins are inclusive of
VEGF (angiogenesis), PDGF (tumor growth), and TGFα (tumor growth).

Future Research
b
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Figure 2. HLRCC PDX Animal Model. (a) HLRCC was implanted into NOD scid mice
and passaged 3 times before being harvested. (b) Cutaneous HLRCC PDX tumors
growth in mice during passage process. (c) Harvesting of cutaneous HLRCC PDX
tumor tissue.
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Figure 4. Histology of HLRCC PDX tissue and HLRCC patient tissue. (a, c)
HLRCC patient tissue histology. (b, d) HLRCC PDX tissue histology.

• Look toward treating HLRCC PDX mice with drugs that inhibit the activity of
specific enzymes and transcription factors such as HIF or VEGF
• Create a database for MD Anderson patients with FH-deficient type 2 papillary
RCC in order to draw relationships for future research projects
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